Batavia Bioservices Email Format

Biotechnology ResearchSouth Holland, Netherlands51-200 Employees

Batavia Biosciences operates as a science-led contract development and manufacturing organization within biotechnology research, guiding biopharmaceutical programs from molecular cloning through GMP-grade manufacturing and the release of material for early clinical trials. Clients describe the business as more than a conventional CDMO, viewing it as a collaborative partner for product development and strategic input. It is based in Leiden, South Holland, Netherlands, and works with partners across Europe and the United States to support early-stage programs.

It specializes in the initial stages of product development, including constructing genetic materials, creating mammalian cell lines, refining upstream production, developing purification steps, and characterizing products for clinical manufacturing. In 2021, the CJ Group acquired Batavia Biosciences. In 2025, Batavia announced a new upstream bioprocessing method built on its HIP-Vax platform intended to improve polio vaccine production.

Sign up for free to view info

Company overview Employee directory